2022 was an eventful year for Trellus, with the launch of the platform and first (modest)revenues generated. Y/E cash of $19.1m was around $2.0m better than our expectations and gives Trellus a cash runway into 2025. The company is now embarking on commercialisation, with the first B2B2C contracts signed and paying subscribers onboarded to the platform. Building a body of RWE is critical to future business development activities around rolling the platform out at scale and active discussions continue with a number of large payers, employers and pharma companies. We look forward to further updates in due course.
